Leerink Swann

In a report published Tuesday, Leerink Swann analyst Ana Gupte initiated coverage on Humana (NYSE: HUM) with an Outperform rating and $120.00 price target. In the report, Leerink Swann noted, “We are initiating coverage on 9 companies within US Managed Care. We expect upside to 2014E EPS from...

In a report published Tuesday, Leerink Swann analyst Ana Gupte initiated coverage on Molina Healthcare (NYSE: MOH) with a Market Perform rating and $35.00 price target. In the report, Leerink Swann noted, “We are initiating coverage on 9 companies within US Managed Care. We expect upside to 2014E...

In a report published Tuesday, Leerink Swann analyst Ana Gupte initiated coverage on Health Net (NYSE: HNT) with a Market Perform rating and $31.00 price target. In the report, Leerink Swann noted, “We are initiating coverage on 9 companies within US Managed Care. We expect upside to 2014E EPS...

In a report published Tuesday, Leerink Swann analyst Ana Gupte initiated coverage on Centene Corp. (NYSE: CNC) with an Outperform rating and $68.00 price target. In the report, Leerink Swann noted, “We are initiating coverage on 9 companies within US Managed Care. We expect upside to 2014E EPS...

In a report published Tuesday, Leerink Swann analyst Ana Gupte initiated coverage on CIGNA Corporation (NYSE: CI) with an Outperform rating and $106.00 price target. In the report, Leerink Swann noted, “We are initiating coverage on 9 companies within US Managed Care. We expect upside to 2014E EPS...

In a report published Tuesday, Leerink Swann analyst Ana Gupte resumed coverage on Aetna (NYSE: AET) with a Market Perform rating and $72.00 price target. In the report, Leerink Swann noted, “We are initiating coverage on 9 companies within US Managed Care. We expect upside to 2014E EPS from...

In a report published Monday, Leerink Swann analyst Marko Kozul reiterated an Outperform rating on Cempra (NASDAQ: CEMP), and raised the price target from $11.00 to $17.00. In the report, Leerink Swann noted, “We are transitioning coverage of CEMP with a new DCF-based $17 price target (PT) and...

In a report published Thursday, Leerink Swann analyst Dan Leonard downgraded the rating on Cellular Dynamics International (NASDAQ: ICEL) from Outperform to Market Perform, but reiterated the $15.00 price target. In the report, Leerink Swann noted, “We've reduced our forward revenue estimates for...

In a report published Tuesday, Leerink Swann analyst Joseph P. Schwartz downgraded the rating on Synageva BioPharma Corp. (NASDAQ: GEVA) from Outperform to Market Perform, and lowered the price target from $66.00 to $62.00. In the report, Leerink Swann noted, “We are downgrading GEVA shares from...

In a report published Friday, Leerink Swann analyst Seamus Fernandez downgraded Sanofi (NYSE: SNY) from Outperform to Market Perform and lowered the PT from €83 ($113.7142) to €80 ($109.6191) based on low visibility in the company's recovery. Fernandez noted that this valuation does not include...

In a report published Thursday, Leerink Swann analyst Joseph P. Schwartz reiterated an Outperform rating on The Medicines Company (NASDAQ: MDCO), and raised the price target from $40.00 to $42.00. In the report, Leerink Swann noted, “At today's analyst meeting, MDCO reviewed the status of its...

In a report published Thursday, Leerink Swann analyst Marko Kozul upgraded the rating on Cubist Pharmaceuticals (NASDAQ: CBST) from Market Perform to Outperform, and raised the price target from $57.00 to $76.00. In the report, Leerink Swann noted, “We are transitioning coverage of CBST with an...

In a report published Wednesday, Leerink Swann analyst Joseph P. Schwartz reiterated an Outperform rating and $22.00 price target on Insmed (NASDAQ: INSM). In the report, Leerink Swann noted, “With potentially pivotal but simultaneously proof-of-concept Arikace non-tuberculous mycobacteria (NTM)...

BMO Capital upgraded Navistar (NYSE: NAV) from Underperform to Market Perform. The target price for Navistar International has been raised from $20 to $35. Navistar's shares traded at $31.85 at the time of publication, down 7.17 percent from its Monday close at $34.31. Analysts at Macquarie...